Status:
COMPLETED
Direct Acting Anti-Viral's In Chronic HCV Patients
Lead Sponsor:
Getz Pharma
Conditions:
Safety Issues
Eligibility:
All Genders
18+ years
Brief Summary
The objective of the study is to determine the safety of DAA's among chronic HCV patients. The outcomes of the study are; To determine the frequency of adverse events while receiving DAAs with or with...
Detailed Description
The cross sectional survey data will be collected on a pre-defined questionnaire from Gastroenterologist and Hepatologist. The questionnaire will provide us information on demographics, relevant patie...
Eligibility Criteria
Inclusion
- Written informed consent
- Male or Female patient
- Age of patient ≥18 years
- Patients already diagnosed with HCV and on DAAs therapy.
Exclusion
- Written informed consent
- Male or Female patient
- Age of patient ≥18 years
- Patients already diagnosed with HCV and on DAAs therapy.
Key Trial Info
Start Date :
May 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2019
Estimated Enrollment :
511 Patients enrolled
Trial Details
Trial ID
NCT04664894
Start Date
May 15 2018
End Date
May 30 2019
Last Update
December 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liver Center Faisalabad
Faisalabad, Punjab Province, Pakistan